6-[3-methylsulfonyl-2-(2H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline
C18H16F3N5O2S — CID 130230590
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-[3-methylsulfonyl-2-(2H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline
6-[3-methylsulfonyl-2-(2H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline (PubChem CID 130230590) has the molecular formula C18H16F3N5O2S and a molecular weight of 423.42 g/mol. Its IUPAC name is 6-[3-methylsulfonyl-2-(2H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline.
Molecular Properties
| Compound Name | 6-[3-methylsulfonyl-2-(2H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline |
|---|---|
| PubChem CID | 130230590 |
| Molecular Formula | C18H16F3N5O2S |
| Molecular Weight | 423.42 g/mol |
| Exact Mass | 423.10 |
| IUPAC Name | 6-[3-methylsulfonyl-2-(2H-tetrazol-5-yl)-4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline |
| SMILES | CS(=O)(=O)c1c(C(F)(F)F)ccc(-c2ccc3c(c2)CCNC3)c1-c1nn[nH]n1 |
| InChI | InChI=1S/C18H16F3N5O2S/c1-29(27,28)16-14(18(19,20)21)5-4-13(15(16)17-23-25-26-24-17)11-2-3-12-9-22-7-6-10(12)8-11/h2-5,8,22H,6-7,9H2,1H3,(H,23,24,25,26) |
| InChIKey | YBAWVDGTBINIOE-UHFFFAOYSA-N |
| XLogP | 2.60 |
| TPSA | 100.63 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 423.42 |
| LogP ≤ 5 | 2.60 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 130230590 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.